Zobrazeno 1 - 10
of 83
pro vyhledávání: ''
Autor:
Jiexian Ma, Xiaohua Wang, Zhaoling Zou, Mixue Xie, Jingsheng Hua, Youdao Liang, Min Wu, Ruyu Yang, Yingwei Hu, Yu Xu, Yanhui Xie, Xiujin Ye, Xiaoqin Wang
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(10)
Background Decitabine are used in the treatment of myelodysplastic syndrome (MDS), but none trials reported overall survival improvement. Methods High-risk MDS and MDS transformed AML (sAML) patients (IPSS-R > 4.5, age above 60 years) in 6 medical ce
Autor:
Catarina Dantas Rodrigues, Fernando Príncipe, Catia L Gaspar, João Paulo Fernandes, Pedro Chorão, Lídia Alves Ribeiro, Daniela Alves, M Eduarda Couto, Rita Coutinho, Henrique Coelho, Margarida Badior, Pedro de Vasconcelos M, Rita Pinho Peixeiro, Diana Viegas, Maria Gomes da Silva, Sérgio Chacim, Ana Tome
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(11)
Introduction Treatment of Splenic (SMZL) and Nodal (NMZL) Marginal Zone Lymphoma is not consensual. Histologic transformation (HT) to aggressive lymphoma is a poorly understood event, with an unfavorable outcome. Objectives Describe the clinical char
Autor:
Kannan Thanikachalam, Hiba Jabbour-Aida, Han Xiaoxia, Oleksandra Lupak, Josephine Emole, Shatha Farhan, Peter Xie
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(8)
Most guidelines recommend induction therapy followed by autologous hematopoietic cell transplantation. A Surveillance, Epidemiology, and End Results-Medicare database analysis from 2000 to 2011 noted a lower use of HCT and bortezomib among Black pati
Autor:
Meryem Colak, Zübeyde Nur Özkurt, Gulendam Bozdayi, Shakhnoza Sarzhanova, Zeynep Arzu Yegin, Isil Fidan
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(5)
Introduction Epstein-Barr virus (EBV) is associated with different types of human malignancies, including Burkitt lymphoma, nasopharyngeal carcinoma, and lymphomas. We retrospectively investigated the presence of EBV-DNA by real-time PCR in clinical
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(8)
Acute myeloid leukemia (AML) is a hematological malignancy originating from myeloid precursor cells, with different cytogenetic abnormalities, genetic mutations and diverse clinical prognoses. We investigated the clinical characteristics, treatment p
Autor:
Auro Viswabandya, Wilson Lam, Sunu Cyriac, Shiyi Chen, Ivan Pasic, Rajat Kumar, Jeffrey H. Lipton, Armin Gerbitz, Eshrak Al-Shaibani, Arjun Law, Zeyad Al-Shaibani, Jonas Mattsson, Fotios V. Michelis, Dennis Dong Hwan Kim
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(6)
Background Allogeneic hematopoietic cell transplantation (HCT) outcomes may be predicted by published risk scores; however, the ideal system has not been identified for acute leukemias. Patients and Methods We retrospectively examined the Hematopoiet
Autor:
Donna L. Forrest, Jennifer White, Heather J. Sutherland, Stephen H. Nantel, Alina S. Gerrie, Kevin W. Song, Maryse M. Power, Thomas J. Nevill, Cynthia L. Toze, Hatem M. Alahwal, David Sanford, Hannah M. Cherniawsky, Florian Kuchenbauer, Sujaatha Narayanan, Yasser Abou Mourad, Leo Escano
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(7)
Despite improvements in therapy, approximately 5% of patients who undergo autologous stem cell transplantation (ASCT) experience early mortality (EM), death within 1 year of transplant (EM post-ASCT). Such patients tend to have few comorbidities sugg
Evaluating Race and Time to Transplantation in Multiple Myeloma: The Mount Sinai Hospital Experience
Autor:
Amir Steinberg, Darren Pan, Jung-Yi Lin, Umut Ozbek, Zachary Galitzeck, Solmaz F. Afshar, Alexander Coltoff
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(7)
Background Previous studies have found that Black patients with multiple myeloma undergo autologous stem-cell transplantation (ASCT) less frequently than their white counterparts, although the factors leading to decreased access and utilization have
Autor:
Charalambos Andreadis, Swetha Kambhampati, Miguel Hernandez Pampaloni, Lawrence D. Kaplan, Weiyun Z. Ai, Thomas Martin, Chiung Yu Huang, Lloyd E. Damon, Andrei Varnavski, Bradley D. Hunter, Bita Fakhri
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(4)
Background More than one-half of high-risk patients with relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) relapse after autologous hematopoietic cell transplantation (auto-HCT). In this phase II study, we investigate the long-term outco
Clearance of Hepatitis C Virus (HCV) Is Associated With Improved Outcomes in HCV-Associated Lymphoma
Autor:
Rumaisa Hameed, Valentina Baez-Sosa, Sanjal H. Desai, Tripti Adhikari, Anusha Vakiti, Emily Paku, Vera Malkovska, Ghassan Al-Shbool, Stephen Fernandez, Facundo E. Stingo, Dawn Fishbein
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(2)
Background Improved hepatitis C virus (HCV) clearance due to directly acting antiviral agents has led to remarkably improved outcomes of indolent HCV-associated non-Hodgkin lymphoma (NHL). The impact of directly acting antivirals on the outcomes of a